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Abstract 
Background: Antibiotic stewardship efforts often support the use of viral diagnostics to 
distinguish viral from bacterial in respiratory infections. However, the utility of respiratory 
viral panels to identify a broad spectrum of viral pathogens and reduce unnecessary 
antibiotic consumption is unclear. This review systematically examined studies of these 
molecular diagnostics to evaluate the current evidence for their use in stewardship 
efforts. 
Methods: I conducted a search of PubMed, Embase, Web of Science, Cochrane 
Library, and ClincalTrials.gov. Eligible studies included randomized controlled trials and 
prospective cohort studies that examined the effect of respiratory viral panels 
(concurrently examining >3 viral pathogens) for adults on changes in antibiotic 
prescribing habits, antimicrobial resistance patterns, or economic outcomes. 
Results: I included eight studies, six randomized controlled trials and two prospective 
cohort studies. Studies were mostly low to moderate quality. Four studies showed some 
small changes in antibiotic use, but effects were inconsistent and not sustained. Four 
studies failed to show any reductions in inappropriate antibiotic utilization at all. No 
studies reported data on changes in antimicrobial resistance patterns and only two 
reported cost data. 
Conclusions: Insufficient evidence exists to recommend respiratory viral panel testing 
as a tool to reduce unnecessary antibiotic exposure and combat antimicrobial 
resistance. A large multi-center randomized controlled trial with blinding and concurrent 
cost and resistance analysis would be required. However, future stewardship research 
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efforts should focus on the decision-making inputs providers use and study diagnostics 
that more closely match these inputs. 
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Introduction 
Background & Significance: Since the discovery and mass production of 
antibiotics in the 20th century, their use has become fundamental to nearly every facet of 
our health system, regardless of setting and level of resources. However, with rising 
rates of resistance to these therapies and stagnated development of novel 
antimicrobials, the long-term effectiveness of these treatment options is threatened. The 
World Health Organization warns that a post-antibiotic era, in which routine injuries and 
infections may become fatal, looms as a realistic possibility this century.(1) While the 
development of some form of antimicrobial resistance is posited as an inevitable 
consequence of use, many stewardship interventions have the intent of slowing or 
altogether halting the development of future resistance.  
The overuse of antibiotics for viral respiratory infections is an avoidable scenario 
with far-reaching consequences on patient outcomes and antimicrobial resistance.(2)(3) 
Improved diagnostic assays for respiratory viruses have the potential to prevent such 
unnecessary use, provided that the testing is accessible to clinicians and results are 
available quickly.(4) By identifying viral pathogens—against which antibiotics have no 
effectiveness—that may explain a patient’s symptoms, clinicians may be able to avoid 
or discontinue antibiotic administration. While the improved ability to detect a high 
number of respiratory viruses may, in theory, lead to reductions in antibiotic use and 
therefore fever antibiotic-resistant infections, there are no systematic studies on the link 
between broad respiratory viral testing and antibiotic utilization. 
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There is no specific therapy for most of the viral pathogens detected by current 
commercially available diagnostic assays, with the important exception of influenza. 
Influenza in particular is known to cause both severe upper and lower respiratory tract 
illness, resulting in up to 35.6 million cases and 56,000 deaths annually in the United 
States alone.(5) An influenza diagnosis is useful in guiding antiviral therapy, which 
includes two classes of antivirals, neuraminidase inhibitors and adamantanes.(6) While 
the usefulness of influenza testing to guide antiviral therapy is known, the utility of an 
influenza diagnosis in preventing antibiotic prescribing is less certain. Meaningful 
analysis of the effectiveness of broad respiratory viral testing must account for the ability 
to identify influenza and initiate effective antiviral therapy. 
For the remaining common respiratory viruses, such as respiratory syncytial virus 
(RSV), no effective antimicrobial therapy exists. Therefore, the utility of any specific 
non-influenza viral diagnosis in common clinical practice is almost entirely for supportive 
care and avoidance of unnecessary antibiotic treatment.  Several diagnostic options for 
these clinical scenarios exist. Older viral culture methods have largely been replaced 
due to their long turnaround time and inadequate sensitivity and specificity. Polymerase-
chain-reaction (PCR) based assays amplify viral DNA or RNA sequences directly from 
patient specimens and generally offer improved sensitivity and specificity over older 
methods. However, earlier-generation PCR tests, while reliable, sensitive, and specific, 
generally required highly trained staff and could still take several days to result. 
 The next step in the application of PCR for viral pathogen detection in clinical 
care was the development of rapid integrated multiplex PCR systems to detect a wide 
variety of respiratory viruses and bacteria in one test. For example, a single assay may 
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be able to identify influenza, respiratory syncytial virus (RSV) parainfluenza virus (PIV), 
adenovirus, coronavirus (CoV), and human metapneumovirus (hMP). The first such 
assays were approved by the US Food and Drug Administration (FDA) in 2007, with at 
least 11 other similar assays now approved.(7) A systematic review and meta-analysis 
of these respiratory viral panels found them to have high diagnostic accuracy, with area 
under receiver operating characteristic (ROC) curve greater than 0.98 for most common 
pathogens.(8) However, both the purchase and day-to-day use of these diagnostics is 
expensive, and their effectiveness in improving clinical outcomes warrants review of 
their use—particularly addressing the question of how they affect antibiotic 
prescribing.(9)  
The evidence base for the use of these viral diagnostics as a tool to combat 
antimicrobial resistance is uncertain. A recent high-quality, quantitative systematic 
review on the testing for influenza, and an accompanying high-quality randomized 
controlled trial (RCT) on rapid influenza, respiratory syncytial virus (RSV), and the 
bacterial pathogen Streptococcus pneumoniae testing found no association between 
these diagnostics and antibiotic prescribing or clinical outcomes.(10) Yet the overall 
applicability of this study is hampered by its use of a rapid device with very low 
sensitivity compared to now standard rapid-PCR based methods that have higher 
sensitivities for influenza—although even current methods show considerably lower 
sensitivities in adult populations when compared to children.(11)(12) A related question 
in pediatric populations has been addressed through systematic review, which did not 
find convincing evidence that respiratory viral testing in EDs lowers antibiotic use.(13) A 
systematic review that examines the effectiveness of currently available multiplex 
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respiratory pathogen detection assays in preventing unnecessary antibiotic use in adults 
has not been performed and is the objective of this study. 
Objectives: This review examined the current evidence for whether broad panel 
respiratory viral testing in adults improves the rate of antibiotic administration and 
antimicrobial resistance. I examined randomized controlled trials and prospective cohort 
studies that addressed the efficacy of these molecular diagnostic pathogen detection 
technologies in improving both provider decision making and patient outcomes.  
 
Methods 
Protocol:  I developed the study objectives and inclusion criteria prior to 
performing the full systematic review, but I did not register a protocol a priori. 
Eligibility Criteria: I included randomized controlled trials that examined the 
relationship between broad respiratory viral testing and provider decision making, direct 
patient outcomes, or antimicrobial resistance patterns in this review as the preferred 
study of choice. I also included prospective cohort studies due to the small number of 
available randomized controlled trials. 
I excluded retrospective cohort studies due to concern over the difficulty 
separating the effects of different parallel antimicrobial interventions retrospectively. I 
similarly excluded pre-post intervention studies because of the high likelihood of broad 
concurrent antimicrobial stewardship in most clinical settings contaminating the effect of 
respiratory viral testing alone. Additionally, the inability to infer reasons for clinical 
decision-making retrospectively and the idea that neither antibiotic administration nor 
respiratory viral testing are rare enough events to necessitate large retrospective 
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reviews made retrospective study designs and pre-post studies less attractive for this 
review.  The full table for eligibility criteria of participant, intervention, comparison, 
outcomes, study design, and setting for this study can be found on page 31.  
Information sources: I searched PubMed, Embase, Web of Science, and 
Cochrane Libraries for available articles using a standardized search between all 
databases. I searched ClinicalTrials.gov to identify unpublished or missing studies. I did 
not impose date or regional restrictions, and articles in English or translated articles with 
an English abstract/title were included. Database searches were most recently 
performed on 28 June 2018. 
Search: Full search forms can be found in Appendix 1. My search was 
developed with assistance from full-time professional librarians who specialize in 
systematic reviews. Terms searched included “molecular diagnostic test”, “respiratory 
pathogen panel”, “polymerase chain reaction”, “multiplex” with synonyms.  The names 
of all multiplex respiratory nucleic-acid amplification tests approved by US FDA at time 
of study were also included. Searches also needed to have “respiratory” and searches 
were limited to randomized controlled trials or prospective cohort studies. 
ClinicalTrials.gov was searched using similar terms to identify any indication of 
publication bias or selective outcome reporting. 
Data collection forms and items: I used Covidence software to compile 
literature(14) and extracted data using a modification of the Cochrane Public Health 
Group Data Extraction template.(15) All data were extracted by me. I did not attempt to 
obtain unpublished data from investigators. Data were sought for study name, year of 
publication, location, study design, size of study, reported changes in antibiotic 
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management, hospital length of stay and readmission rates, changes to isolation 
procedures, economic outcomes, and any measured or estimated economic outcomes 
included in the study. 
Risk of bias (individual studies):  I used validated risk of bias tools to assess 
risk of bias. Risk of bias within randomized controlled trials was assessed using 
standardized Cochrane Risk of Bias tool for RCTs within Covidence software, found in 
Appendix 2. The Newcastle-Ottawa Quality Assessment Scale was used to assess 
quality of prospective cohort studies, found in appendix 3.(16)  
Synthesis of Results: I synthesized results qualitatively and summarized them 
given expected variability in reporting, intervention type, timepoints, and location.  
Risk of bias across studies: ClinicalsTrials.gov was searched for unpublished 
studies to identify any indication of publication bias or selective outcome reporting.  
Additional Analyses: As describe above, I specified only a qualitative analysis 
prior to study creation. 
 
Findings 
Study selection: Searching PubMed, Embase, Web of Science, and Cochrane 
Library databases resulted in 768 combined articles from all database sources, which 
equaled 448 eligible for screening after duplicates were removed. Screening of title and 
abstracts from these studies resulted in 24 being considered for full-text review. Of 
these, 8 studies were eligible, including 6 randomized controlled trials (17)(18)(19)(20) 
(21)(22) and 2 prospective cohort studies.(23)(24) (See PRISMA diagram in Figure 1 on 
page 27). Detailed descriptions of the selected studies and individual risk of bias ratings 
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is found in table 3, with study characteristics and results found in table 4. Overall, the 8 
studies included in this review failed to show a significant and sustainable effect of 
respiratory viral panel testing on antibiotic use and antimicrobial resistance patterns. 
Using the strength of evidence guidelines recommended by the US Evidence-based 
Practice Center (EPC) in 2009, I evaluated the evidence from this review on the basis of 
risk of bias, consistency, directness, and precision, risk of publication bias, and 
applicability.(25)  
 Risk of bias within studies: The overall risk of bias within the individual studies 
is moderately high, as seen in table 3. Specifically, while only high-quality study designs 
(randomized controlled trials and prospective cohort studies) were included in the 
analysis, the overall quality of these studies is moderately low. The lack of blinding for 
outcomes assessors in four out of six of the randomized controlled trials is detrimental 
to overall quality. Also, given that the interventions examine provider behavior and 
prescribing habits, a study effect to bias toward a null result is possible. Specifically, it is 
possible that providers may become more aware of and compliant with “best practices” 
such as restricted antibiotic use for viral infections in both control and intervention arms 
of a study, reducing the magnitude of difference between two groups. This risk is 
heightened by the lack of provider blinding in any of the studies examined. However, 
only one study assessed for this risk using historical data as a comparator, making it 
difficult to estimate an overall study effect on interventions. 
 Changes in antibiotic utilization: All eight studies included data about the 
primary outcome of interest—changes in antibiotic utilization. Three studies compared 
the use of broad PCR-based respiratory viral testing to routine care. Only one of those 
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studies showed a significant difference in antibiotic management—a modest decrease 
in outpatient prescription rates at the initial visit that no longer existed after 10-day 
follow-up (as described by Brittain-Long et al. 2011.) The other two studies did not show 
any significant changes in antibiotic management attributable to these diagnostics.  
Four studies compared the use of rapid multiplex respiratory viral panels with 
slower laboratory-based PCR, including three randomized controlled trials and one 
prospective cohort study. Two studies showed no significant effect on antibiotic 
management at all. This included a prospective cohort study (Semret et al. 2017) that 
found no significant effect of rapid multiplex testing on antibiotic management. The other 
study that found no effect was a quasi-randomized controlled trial (Andrews et al. 2017) 
that reported no significant effect on patients receiving antibiotics, time to receiving 
antibiotics, or duration of antibiotic usage. In Gilbert et al. (2016), all patients received a 
standard bundle of diagnostics that included blood procalcitonin levels and a common 
core of other diagnostic tests. They were then randomized to receiving additional rapid 
multiplex testing. This study showed that those with multiplex testing did receive fewer 
antibiotics, but that duration of treatment did not decrease. The fourth study examining 
this intervention (Brendish et al. 2017) did find that rapid multiplex testing improved 
rates of antibiotic discontinuation but did not have a significant effect on overall rates of 
antibiotic prescribing or duration.  
A similar trial by Branche et al. (2015) randomized patients to receiving standard-
of-care laboratory testing or a combined protocol with respiratory viral multiplex and 
blood procalcitonin. They found a significant effect of this protocol on duration of 
antibiotic treatment amongst adherent patients but did not find a significant effect on 
 9 
number of patients receiving antibiotics and did not attempt to determine the effect of 
viral testing alone. 
 Changes in length-of-stay or isolation: Of the studies described, five reported 
length-of-stay outcomes associated with broad respiratory viral testing. Only one study 
(Brendish et al. 2017) found a significant difference in hospital length-of-stay, which was 
a modest 1-day decrease. The other four studies that reported length-of stay did not find 
that testing had an effect. The same study (Brendish et al 2017) was the only study to 
report the effect on isolation protocols and found that testing had no significant effect.  
Economic outcomes: Only two out of eight studies included economic 
information about their intervention. Oosterheert et al. (2005) reported that their 
laboratory PCR-based viral respiratory testing increased overall treatment and 
diagnostic costs by €318.17 per patient in 2005 currency at a Dutch academic medical 
center, after concluding that the intervention provided no significant effect on antibiotic 
management or length-of-stay. Gilbert et al. (2016) reported that the median cost of 
therapy during the course of hospitalization was lower by $4916 (US currency, 2016) in 
the intervention group guided by procalcitonin and respiratory viral panel testing but did 
not attempt to discern the effect of only respiratory testing. From these two studies it is 
not possible to assess the overall cost effectiveness of respiratory viral panel testing 
alone. 
 Consistency: This review does find moderate consistency of the effect sizes and 
direction within the evidence base. Specifically, there is moderately consistent evidence 
that respiratory viral panel testing does not provide strong sustained improvement in 
antibiotic management. Short-term differences in prescribing habits are suggested by a 
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Brittain-Long et al. (2011) outpatient RCT, while three studies (Brendish et al. 2017, 
Gilbert et al. 2016, and Branche et al. 2017) suggest that multiplex respiratory viral 
testing may play a small role in lowering the number or duration of empiric antibiotic 
therapies. However, all studies reported a failure to show a convincing overall 
improvement in antibiotic administration as the result of this testing.  
 Directness: The causal connection between the use of respiratory viral panel 
testing and community resistance patterns is moderate. The direct final outcome of 
interest within antibiotic stewardship initiatives –the effect of these diagnostics on 
community antimicrobial resistance patterns—was not reported in any capacity by any 
study within this review. Intermediate measures such as overall antibiotic prescribing 
and administration serve as useful proxy measures but are upstream indicators of 
overall antibiotic stewardship goals. Other important patient outcomes related to 
antibiotic overuse include rate of related nosocomial Clostridium difficile infections or 
antibiotic-associated adverse drug events. (26)(27) None of the studies included in this 
review reported either of these outcomes as part of their study.  
 Precision: Although I did not perform a quantitative meta-analysis, the precision 
of estimate is low for this review. This imprecision is in part due to the lack of several 
large, high-quality RCTs and in part due to disparate intervention definitions. The 
inclusion of laboratory based viral respiratory PCR panel testing, rapid point-of-care-test 
respiratory viral panel testing, and procalcitonin with respiratory viral testing creates a 
diversity of interventions that prevents precise estimates. However, the lack of any of 
these studies showing strong and sustainable improvements in antibiotic management 
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attributable to these tests suggests they generally have limited utility in changing 
provider behavior, even if the point measurement is uncertain. 
Publication bias: In a search of ClinicalTrials.gov, I found 197 results, including 
6 relevant studies without results posted that would likely have fit inclusion criteria for 
this review. Four of those results were in the enrollment or pre-enrolling stages, 
meaning they were unlikely to contribute to publication bias. Two relevant studies had 
been completed without posted results. My search of PubMed and ResearchGate for 
both studies confirmed that no results had been published for either study.  
The first protocol, labeled “Rapid Viral Diagnostics in Adults to Reduce 
Antimicrobial Consumption and Duration of Hospitalization” was a randomized 
controlled trial in Oulu, Finland comparing immediate release of multiplex respiratory 
viral panel test results to withholding those results from providers for 7 days. (28) The 
intended outcomes of that study were the length of hospitalization and change in 
antibiotic consumption attributable to the results of this diagnostic. I did not attempt to 
contact the author for additional data. The effect this unpublished study may have on 
the overall risk of publication bias within this review is unclear. Another completed 
randomized controlled trial titled “Rapid Diagnostics for Upper Respiratory Infections in 
the Emergency Department (URI DxED)” examining rapid diagnostics in the Emergency 
Department was only completed two months prior to this review and is likely a 
forthcoming publication. (29) 
Additionally, several studies failed to show significant effects of their 
interventions, suggesting a willingness to publish negative studies and lowering the risk 
of publication bias. However, the existence of unpublished or withheld data that bias the 
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published results cannot be excluded without direct communication with the authors, 
which did not occur in this review. While the search tool resulted in finding studies 
referenced in hand-searches, full sensitivity of the search instrument cannot be 
guaranteed.  Also, the exclusion of retrospective studies may have resulted in omission 
of several important studies, although the rationale for such exclusions is discussed 
above. Overall, the potential for bias across studies within this review is considered low. 
The full breadth of this study would need to be re-assessed in 2 to 4 years to include 
possible forthcoming studies.  
 Applicability: The evidence base from this review is most applicable to inpatient 
and emergency room settings in high-income countries. The existence of only one study 
examining the effects of respiratory viral panel testing in an outpatient setting limits the 
ability to extrapolate results to ambulatory settings. Additionally, all eight studies were 
conducted in either the United States, Canada, or Europe. Although the issue of 
antibiotic use and stewardship in low-and middle-income countries is of great 
importance, the studies within this review do not provide strong evidence applicable to 
those settings.(30) 
Summary of evidence:  A systematic review of 448 unique articles and 
qualitative synthesis of 8 studies representing 3208 subjects failed to show any overall 
significant, sustainable decrease or alteration in antibiotic use caused by respiratory 
viral panel testing. However, four studies did show some aspect of antibiotic prescribing 
improved by a form of respiratory viral panel testing. Specifically, in an outpatient 
randomized controlled trial, Brittain-Long et al. (2011) showed that access to respiratory 
viral panels reduced antibiotic prescription rates at the initial visit, but that difference 
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was not significant after 10-day follow-up. In a pragmatic randomized controlled trial, 
Brendish et al. (2017) showed that rapid multiplex respiratory viral panel testing had a 
small effect on discontinuation of empiric therapy after a positive viral diagnosis, but that 
testing did not reduce the overall likelihood of receiving antibiotic therapy.  
Two randomized controlled trials examining procalcitonin guidance combined 
with multiplex respiratory viral testing showed conflicting results. First, Branche et al. 
(2015) showed a small decrease in the duration of antibiotic therapy only among 
adherent patients but did not see an overall decrease in the number of patients 
receiving antibiotics. In contrast, a similar intervention by Gilbert et al. (2016) did not 
report a decrease in duration of antibiotic therapy but did report a decrease in the total 
number of antibiotics administered. Four other studies that met inclusion criteria 
reported no change to antibiotic administration attributable to respiratory viral panel 
interventions.  
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Discussion 
The evidence is insufficient for any single intervention to support a 
recommendation that either strongly endorses use or avoidance of these tests. 
However, the existing evidence does not support use of broad pathogen respiratory viral 
panels as a “magic bullet” tool to improve antibiotic stewardship. Prior systematic 
reviews have highlighted the ability of respiratory pathogen panels to accurately identify 
specific viral pathogens. Yet despite their diagnostic accuracy, this review fails to find 
convincing evidence to recommend the tests’ use as a means of reducing unnecessary 
antimicrobial exposure. This review in fact finds weak to moderate evidence that their 
use does not improve these outcomes. There is insufficient evidence to comment on 
their cost-effectiveness. 
A large multi-center randomized controlled trial would be required to generate 
definitive evidence of respiratory viral panel testing’s contribution to antibiotic 
stewardship efforts. Such a study would need to be powered to detect a small reduction 
in antibiotic use as a primary outcome and would also be well-served by concurrently 
collecting data on antimicrobial resistance patterns, antibiotic-associated adverse drug 
events, Clostridium difficile infections, hospital length-of-stay, re-admission rates, and 
mortality. To provide useful evidence to policymakers, the study would need to include 
economic analyses such as a cost-consequence or cost-effectiveness study and in-
depth surveys of provider attitudes to guide best practices, retraining, and reeducation 
of providers. Blinding of data assessors is also crucial. and blinding of patients 
themselves to the diagnostic-option their providers chose for them would bolster study 
quality. Additional study variables should include radiographic suspicion of bacterial 
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pneumonia, ICU status, smoking status, age, sex, comorbidities (in form of Charlson 
Comorbidity Index), presence of immunocompromise or cystic fibrosis, seasonality, 
trends in community viral prevalence at each center, and existing antimicrobial 
stewardship efforts.  
Provider behavior and stewardship: Because the evidence in this review is 
unable to support the use of respiratory viral panel testing as an effective tool to combat 
the growing problem of antimicrobial resistance, it is important to discuss potential 
opportunities, barriers, and future outlook of diagnostics relating to acute respiratory 
viral illness in adults in the context of antimicrobial resistance. Three distinct reasons 
these viral tests may not promote antibiotic stewardship efforts as hoped include 
concern for viral and bacterial co-infections, reliance on initial empiric antibiotic therapy, 
and providers’ hesitation to withdraw antibiotic therapy once initiated. 
 Both viral and bacterial pathogens may exist in a single critically ill patient. Given 
a seemingly unknown risk of concurrent bacterial infection, a viral result alone from a 
respiratory panel may not be re-assuring enough to alter therapy. Although several 
studies have attempted to ascertain the risk of bacterial and viral co-infection in ill adults 
with respiratory tract infections, our ability to identify such co-infections is inadequate. 
(31)(32)(33)(34) Clinicians are likely aware that synergistic viral-bacterial co-infections 
can result in particularly severe illness. For example, influenza and methicillin-resistant 
Staphylococcus aureus (MRSA) coinfection in community-acquired pneumonia is 
associated with much greater risk of mortality than either infection alone.(35) A recent 
systematic review found that bacterial coinfection of influenza patients was often 
common, but that the particular bacteria, pathogen susceptibility profiles, and clinical 
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presentations of patients varied significantly—further introducing uncertainty into the 
case of a patient with known viral respiratory tract infection.(36) The inability to rule out 
bacterial co-infection and concern for severe bacterial-viral co-infection may lead 
clinicians to prescribe antibiotics even in the face of a diagnosed viral infection.  
One diagnostic strategy that has recently gained favor in some stewardship 
efforts to determine the presence of bacterial co-infection is the use of procalcitonin 
levels. Procalcitonin is a blood marker produced during bacterial infections, and is 
purported to be an important marker of bacterial infections.(37) In strong support of 
procalcitonin as a useful tool in antibiotic stewardship efforts is a 2017 Cochrane review 
on the utility of procalcitonin to initiate or discontinue antibiotics in acute respiratory tract 
infections.(38) The review found strong, high-quality evidence that procalcitonin testing 
to guide the initiation and duration of antibiotic therapy resulted in lower risk of mortality 
and improved antibiotic stewardships across a variety of clinical settings. The utility of 
procalcitonin is also addressed in one study in this review (Branche et al. 2015) that 
used procalcitonin as a baseline diagnostic and layered multiplex testing on top of those 
results.  
 Moving beyond just the risk of a co-infection despite a positive viral result is the 
reliance on empiric antibiotic initiation when an ill patient presents to care. Much of this 
empiric antibiotic initiation is evidence-based, including an often-cited 2004 
retrospective study of 18,209 Medicare patients finding that antibiotic initiation within 4 
hours of arrival was associated with improvements in both mortality and length-of-stay. 
(39) Because of this study and the national and international guidelines that followed, 
rapid initiation of empiric antibiotics upon presentation has become widespread for 
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presumed community-acquired pneumonia. The art of narrowing or discontinuing these 
antibiotics following admission is a much more complicated and less evidenced-based 
practice, with guidelines frequently containing weak recommendations and very low-
quality evidence. (40) 
 Indeed, a patient’s improvement after admission and initiation of antibiotics for a 
respiratory tract infection may instill within providers a reluctance to narrow coverage. In 
community-acquired pneumonia there remains controversy over the utility of sputum 
cultures—the mainstay of bacterial identification in lower respiratory tract infections—
because of the poor sensitivity and high variability of the test.(41)  It is frequently difficult 
to discern whether a patient’s improvement is due to antimicrobial therapy or due to 
supportive care and the natural history of a viral infection. 
 These factors, the possibility of simultaneous bacterial and viral infections, the 
reliance on empiric antibiotic therapy, and the reluctance to discontinue antibiotics once 
initiated, combine to undermine the utility of a viral diagnosis in antibiotic stewardship 
efforts. This utility is further undermined by a non-influenza viral diagnosis—meaning 
the resulting pathogen still has no antimicrobial therapy options available. Accordingly, 
this systematic review found a dearth of evidence to support the use of respiratory viral 
panel testing as an antimicrobial stewardship tool. In place of these viral panels, 
stewardship efforts should focus on a new generation of diagnostic efforts to combat 
antibiotic overuse and improve the landscape of antimicrobial resistance. 
 Use of focused rapid influenza testing: The lack of evidence supporting broad 
respiratory viral testing in this review raises the question of whether a narrower, more 
focused diagnostic would be more effective and appropriate. In particular, influenza may 
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be a better target—given effective antiviral therapy, known predictable seasonality, and 
high morbidity and mortality associated with certain strains.(42) Despite lower than ideal 
performance characteristics in adults and the elderly compared with children, most rapid 
molecular assays for influenza still show reliable sensitivity and can be performed 
quickly, from 15 to 90 min.(43) 
 The question of how rapid PCR testing for influenza affects broader respiratory 
viral testing management was not systematically studied in this review. However, two of 
the eight studies included did comment on the clinical utility of a rapid influenza result as 
part of broader multiplex respiratory viral testing. Notably the prospective study by 
Semret et al. (2017) reported that a positive influenza test significantly increased 
likelihood of receiving appropriate antiviral treatment, namely oseltamivir. However, a 
positive influenza result did not lead to statistically significant discontinuation of 
antibiotics when controlled for radiographic evidence of pneumonia. Similarly, a quasi-
randomized study by Andrews et al. (2017) found that a positive influenza diagnosis 
improved the timing of antiviral administration but did not comment on the association of 
an influenza diagnosis alone and antibiotic use. 
 Despite the lack of convincing evidence that rapid influenza testing alone leads to 
decreased antibiotic utilization, the clinical value of these tests is still high. As supported 
by the two aforementioned studies, a positive influenza diagnosis can facilitate 
appropriate antiviral therapy. Even without a corresponding decrease in antibiotic 
therapy, prompt diagnosis and use of anti-influenza therapy improves clinical 
outcomes.(44) As evidence of the value of a rapid influenza diagnosis, a randomized 
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controlled trial where some are ineligible for influenza diagnosis and treatment would 
likely be considered unethical.  
 Policy implications: The use of broad respiratory viral testing has become the 
subject of policy debate—including a recent proposed local coverage determination by 
the US Centers for Medicare & Medicaid Services (CMS) to remove coverage of 
multiplex respiratory viral panels. (45) In this proposed coverage determination, CMS 
discusses whether these tests are “reasonable and necessary” for clinical care. The 
proposed conclusion is that the use of multiplex respiratory pathogen detection panels 
does not provide worthwhile clinical benefit. 
This systematic review does not find evidence to contradict this assertion and 
finds weak evidence that these tests do not reduce the improper use of antibiotics. This 
proposed CMS withdrawal of coverage does not include rapid influenza testing, which 
would remain a covered benefit. A large randomized controlled trial with adequate 
power to detect a small reduction in inappropriate antibiotic would be needed to 
comprehensively assess the clinical benefit of these tests, as discussed above.  
This policy change would result in moving away from a “one-size-fits-all” test for 
respiratory pathogen screening to a more tailored diagnostic approach. Although these 
tests may not adequately change antibiotic prescribing habits, they still may have a use 
in clinical practice. A broad convenient test with strong performance characteristics can 
still be useful to improve surveillance of disease transmission. However, it is likely that a 
tool that detects only common pathogens with effective treatment options available, 
such as influenza, would be a more useful and cost-effective tool. A full cost-
effectiveness analysis from both a societal and healthcare system perspective with a 
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sensitivity analysis corresponding to different seasonal prevalence and vaccination 
efficacy rates would be needed to determine this question in the United States. 
 
Conclusion: The future of antibiotic stewardship diagnostics 
 Improved infectious disease diagnostics are a promising tool in antimicrobial 
stewardship efforts. However, this review is unable to find sufficient evidence to support 
or categorically exclude the assertion that broad respiratory viral testing alone results in 
significant, sustainable reductions in inappropriate antibiotic use.  The example of 
multiplex respiratory viral testing demonstrates that a test may need to rule out all 
reasonable treatable pathogens in order to substantially affect antibiotic prescribing 
behavior. Just as procalcitonin testing shows promise as a method to exclude bacterial 
infection and improve stewardship efforts, diagnostics are also needed to guide existing 
empiric therapy within a known bacterial infection. One example of these diagnostics is 
point-of-care testing for methicillin-resistant Staphylococcus aureus (MRSA).(46) 
Although the overall utility of this specific test in clinical practice is uncertain, diagnostic 
assays that can quickly and reliably determine resistance patterns will be crucial to 
result in evidence-based narrowing of antibiotic treatment of known bacterial infections. 
 Finally, future research must also address the meaningful outcomes of antibiotic 
stewardship efforts: antimicrobial resistance patterns, Clostridium difficile infection, and 
adverse drug events associated with antimicrobial use.(27) In addition to standard 
measures of antibiotic use, such as duration and spectrum of treatment and amount of 
unnecessary antibiotic therapy avoided, studies should focus on the clinical outcomes 
that matter most to patients of those efforts.  
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Table 1: Eligibility criteria for the review  
Criteria Description 
Participants Adults (as considered by investigated district, usually >age 18yo), non-immunocompromised, 
non-cystic fibrosis. 
Interventions Use of broad respiratory viral testing panels, use of rapid (point-of-care test) respiratory viral 
panels. Does NOT include influenza A/B and/or RSV testing alone (or panels of ≤3 viruses) or 
the performance characteristics alone of eligible tests. 
Comparisons Untested individuals, individuals with a negative test (compared to positive result), “routine 
care”, standard laboratory testing (when compared to rapid result). 
Outcomes Changes in antibiotic prescribing, changes in antimicrobial resistance patterns, hospital length-
of-stay, economic outcomes (cost, productivity, etc) 
Study design Randomized controlled trials, prospective cohort studies 
Setting  All clinical settings (inpatient, outpatient, emergency department)  
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Table 3: Description of selected studies and risk of bias rating: 
 
Study Design Study 
Name 
Intervention Comparator Inpatient/ 
Outpatient
/ 
ED 
Country Risk of bias Rating Notes on risk of bias 
rating 
Randomized 
Controlled 
Trials 
Oosterheert 
2005 
TaqMan 
PCR virus 
panel 
identifi-
cation and 
≤48 hr 
reporting 
Test 
performed 
but results 
not given to 
provider 
Inpatient Nether-
lands 
Sequence generation: Low 
risk 
Allocation concealment: 
High risk 
Blinding participants: High 
risk 
Blinding assessors: High 
risk 
Incomplete data: Low risk 
Selective outcome 
reporting: Low risk 
Other bias: Low risk 
Open-label study 
design, and lack of 
blinding either 
participants or 
outcomes assessors 
increased risk of 
bias. 
Brittain-
Long 2011 
Rapid 
respiratory 
viral 
multiplex 
(result 
<48hrs) 
Delayed 
respiratory 
PCR result 
(8-12 days) 
Outpatient Sweden Sequence generation: Low 
risk 
Allocation concealment: 
Low risk 
Blinding participants: High 
risk 
Blinding assessors: High 
risk 
Incomplete data: Low risk 
Selective outcome 
reporting: Low risk 
Other bias: Low risk 
Lack of blinding for 
participants or 
outcomes assessors 
increased risk of bias 
Brendish 
2017 
Rapid 
respiratory 
Routine 
care, 
Inpatient/
ED 
United 
Kingdom 
Sequence generation: Low 
risk 
Overall very high-
quality study. High 
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viral 
multiplex 
(FilmArray) 
including 
standard 
laboratory 
based 
respiratory 
PCR 
Allocation concealment: 
Low risk 
Blinding participants: High 
risk 
Blinding assessors: Low 
risk 
Incomplete data: Low risk 
Selective outcome 
reporting: Low 
Other bias: Low risk 
risk of bias due to 
non-blinding of 
participants/provider. 
However, addressed 
by authors who 
stated blinding non-
viable due to study 
goals to inform 
clinical teams of test 
results as 
intervention. 
Andrews 
2017 
Rapid 
respiratory 
viral 
multiplex 
(FilmArray) 
Standard 
laboratory 
based 
respiratory 
PCR 
Inpatient United 
Kingdom 
Sequence generation: High 
risk 
Allocation concealment: 
High risk 
Blinding participants: High 
risk 
Blinding assessors: High 
risk 
Incomplete data: Low risk 
Selective outcome 
reporting: Low 
Other bias: Unclear risk 
Quasi-randomized 
control format using 
odd-even day of the 
month randomization 
led to high risk of 
bias throughout 
study. Blinding was 
not performed, 
contributing to overall 
risk. Seasonality of 
study (summer 
months) may have 
contributed unclear 
bias on results. 
Gilbert 2016 Rapid 
respiratory 
viral 
multiplex 
(FilmArray) 
Standard 
laboratory 
based 
respiratory 
PCR 
Inpatient/
ED 
United 
States 
Sequence generation: 
Unclear risk 
Allocation concealment: 
High risk 
Blinding participants: High 
risk 
Blinding assessors: High 
Overall low-quality 
study. 
Randomization 
methods not fully 
described. Given 
clustered 
randomization by 
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risk 
Incomplete data: High risk 
Selective outcome 
reporting: High 
Other bias: High risk 
week, allocation non-
concealment and 
non-blinding 
contribute to high risk 
of study bias. High 
rate of non-evaluable 
data, unreported 
rates of 
deaths/adverse 
events, and 
emphasis on 
"potential" antibiotics 
averted result in very 
high overall risk of 
bias. 
Branche 
2015 
Rapid 
respiratory 
viral 
multiplex 
(FilmArray) 
+ pro-
calcitonin 
Standard 
laboratory 
based 
respiratory 
testing 
Inpatient United 
States 
Sequence generation: 
Unclear risk 
Allocation concealment: 
Low risk 
Blinding participants: High 
risk 
Blinding assessors: High 
risk 
Incomplete data: Low risk 
Selective outcome 
reporting: Low 
Other bias: Unclear risk 
Sequence generation 
methods random but 
not reported. Non-
blinded open-label 
study design and 
lack of explicit 
blinding of statistical 
analysts contribute to 
overall risk. Study 
effect on prescribing 
habits possible 
based on reported 
historical controls. 
Prospective 
Cohort 
Studies 
Semret 
2017 
Availability 
of viral PCR 
panel 
results 
Treatment 
prior to viral 
PCR panel 
results 
Inpatient Canada 9* out of 9* possible No deductions. Study 
particularly strong for 
adjusting for 
radiographic 
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suspicion of 
pneumonia. 
Hernes 
2013 
Positive 
respiratory 
viral panel 
result 
Negative 
respiratory 
viral panel 
result; non-
symptomati
c controls 
Inpatient Norway 6* out of 9* possible Two deductions 
coming from poor 
intervention 
comparability. One 
additional deduction 
for pulling controls 
from asymptomatic 
population. 
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Table 4: Study characteristics and individual results: 
 
Intervention 
Group 
Study 
name 
Study type 
Total 
study 
size 
included  
Changes in 
antibiotic 
management 
Changes in 
length-of-
stay 
Changes in 
30-day 
readmission 
rate 
Changes 
to isolation 
procedures 
Changes in 
antimicrobial 
resistance 
patterns 
Economic 
outcomes 
Laboratory 
PCR vs 
routine care 
Oosterheert 
2005 
RCT 107 
No significant 
effect 
No 
significant 
effect 
Not 
reported 
Not 
reported 
Not reported 
PCR 
increased 
treatment 
and 
diagnostic 
costs by 
€318.17 
per 
patient 
(2005) 
Brittain-
Long 2011 
RCT 406 
Access to 
outpatient PCR 
decreased 
antibiotic 
prescription 
rates at initial 
visit, but not 
significant at 
follow-up 
N/A  
(outpatient) 
N/A 
(outpatient) 
Not 
reported 
Not reported 
Not 
reported 
Hernes 
2013 
Prospective 
cohort 
study 
203 
No significant 
effect 
No 
significant 
effect 
Not 
reported 
Not 
reported 
Not reported 
Not 
reported 
Rapid 
multiplex vs 
laboratory 
PCR 
Brendish 
2017 
pragmatic 
RCT 
720 
Rapid multiplex 
did not reduce 
likelihood of 
receiving 
antibiotic 
Rapid 
multiplex 
test 
decreased 
LOS 1 day. 
No change 
No 
significant 
effect  
Not reported 
Not 
reported 
directly 
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therapy. It did 
improve rates 
of provider 
discontinuation 
of antibiotic 
therapy after 
viral diagnosis. 
Andrews 
2017 
quasi-
randomized 
RCT 
545 
No significant 
effect on 
patients 
receiving 
antibiotics, time 
to receiving 
antibiotics or 
duration of 
antibiotic use. 
No change No change 
Not 
reported 
Not reported 
Not 
reported 
Semret 
2017 
Prospective 
cohort 
study 
800 
No significant 
effect 
Not 
reported 
Not 
reported 
Not 
reported 
Not reported 
Not 
reported 
Gilbert 
2016 
Cluster 
RCT 
127 
PCT + 
multiplex 
decreased # of 
antibiotics 
received, but 
did not 
decrease 
overall duration 
of therapy. 
Not 
reported 
Not 
reported 
Not 
reported 
Not reported 
Median 
cost of 
total 
therapy 
lower in 
PCT + 
multiplex 
($3037 vs 
7953, 
2016 
USD) 
Procalcitonin 
+ multiplex 
Branche 
2015 
RCT 300 
No significant 
effect on 
patients 
No change 
Not 
reported 
Not 
reported 
Not reported 
Not 
reported 
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vs laboratory 
PCR 
receiving 
antibiotics, but 
decrease in 
duration of 
antibiotic 
therapy among 
adherent 
patients. 
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Appendix 1: Search Strategies used: 
PUBMED:  
("molecular diagnostic techniques" OR "molecular diagnostic" OR "viral panel" OR "viral panels" 
OR "respiratory pathogen panel" OR "respiratory pathogen panels" OR "nucleic acid test" OR 
"respiratory assay" OR RVP OR "eplex respiratory" OR "esensor respiratory" OR "filmarray 
respiratory" OR rp2 OR nxtag OR "verigene respiratory" OR "rp flex" OR xtag OR "filmarray 
respiratory" OR "panther fusion assay" OR "rp ez" OR ((polymerase OR "polymerase chain 
reaction") AND multiplex) OR (“real-time PCR” AND “respiratory viruses”)) AND respiratory AND 
(prospective OR "prospective studies" OR "randomized controlled trial" OR rct OR "randomized 
controlled" OR "randomised controlled" OR “randomized”) 
 
Web Of Science:  
("molecular diagnostic techniques" OR "molecular diagnostic" OR "viral panel" OR "viral panels" 
OR "respiratory pathogen panel" OR "respiratory pathogen panels" OR "nucleic acid test" OR 
"respiratory assay" OR RVP OR "eplex respiratory" OR "esensor respiratory" OR "filmarray 
respiratory" OR rp2 OR nxtag OR "verigene respiratory" OR "rp flex" OR xtag OR "filmarray 
respiratory" OR "panther fusion assay" OR "rp ez" OR ((polymerase OR "polymerase chain 
reaction") AND multiplex) OR (“real-time PCR” AND “respiratory viruses”)) AND respiratory AND 
(prospective OR "prospective studies" OR "randomized controlled trial" OR rct OR "randomized 
controlled" OR "randomised controlled" OR “randomized”) 
 
Embase:  
('molecular diagnostic techniques'/exp OR 'molecular diagnostic':ti,ab OR 'viral panel' OR 'viral 
panels' OR 'respiratory pathogen panel' OR 'respiratory pathogen panels' OR 'nucleic acid test' 
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OR 'respiratory assay' OR rvp:ti,ab OR 'eplex respiratory' OR 'esensor respiratory' OR rp2:ti,ab 
OR nxtag:ti,ab OR 'verigene respiratory' OR 'rp flex' OR xtag OR 'filmarray respiratory' OR 
'panther fusion assay' OR 'rp ez' OR ((polymerase:ti,ab OR 'polymerase chain reaction'/exp) 
AND multiplex:ti,ab) OR (“real-time PCR” AND “respiratory viruses”)) AND respiratory AND 
(prospective:ti,ab OR 'prospective studies'/exp OR 'randomized controlled trial':it OR rct:ti,ab 
OR 'randomized controlled' OR 'randomised controlled' OR ‘randomized’) NOT 'conference 
abstract'/it 
 
Cochrane Library:  
("molecular diagnostic techniques" OR "molecular diagnostic" OR "viral panel" OR "viral panels" 
OR "respiratory pathogen panel" OR "respiratory pathogen panels" OR "nucleic acid test" OR 
"respiratory assay" OR RVP OR "eplex respiratory" OR "esensor respiratory" OR "filmarray 
respiratory" OR rp2 OR nxtag OR "verigene respiratory" OR "rp flex" OR xtag OR "filmarray 
respiratory" OR "panther fusion assay" OR "rp ez" OR ((polymerase OR "polymerase chain 
reaction") AND multiplex) OR (“real-time PCR” AND “respiratory viruses”)) AND respiratory AND 
(prospective OR "prospective studies" OR "randomized controlled trial" OR rct OR "randomized 
controlled" OR "randomised controlled") 
 
ClinicalTrials.gov: 
"molecular diagnostic techniques" OR "molecular diagnostic" OR "viral panel" OR "viral panels" 
OR "respiratory pathogen panel" OR "respiratory pathogen panels" OR "nucleic acid test" OR 
"respiratory assay" OR RVP OR “multiplex PCR” AND respiratory  
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Appendix 2: Adapted Cochrane Risk of Bias tool for Randomized 
Controlled Trials, Covidence. 
 
Describe the method used to generate the allocation sequence in sufficient detail to 
allow an assessment of whether it should produce comparable groups. 
HIGH  LOW  UNCLEAR 
Comments: 
 
Describe the method used to conceal the allocation sequence in sufficient detail to 
determine whether intervention allocations could have been foreseen in advance of, 
during, enrollment. 
HIGH  LOW  UNCLEAR 
Comments: 
 
Describe all measures used, if any to blind study participants and personnel from 
knowledge of which intervention a participant received. Provide any information relating 
to whether the intended blinding was effective. This domain can have judgements per 
outcome. 
HIGH  LOW  UNCLEAR 
Comments: 
 
Describe the completeness of outcome data for each main outcome, including attrition 
and exclusions from the analysis. State whether attrition and exclusions were reported, 
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the numbers in each intervention group (compared with total randomized participants), 
reasons for attrition/exclusions where reported, and any re-inclusions in analyses 
performed by the review authors. This domain can have judgements per outcome. 
HIGH  LOW  UNCLEAR 
Comments: 
 
 
State how the possibility of selective outcome reporting was examined by the review 
authors and what was found. 
HIGH  LOW  UNCLEAR 
Comments: 
 
 
State any important concerns about bias not addressed in the other domains in the tool. 
If particular questions/entries were re-specified in the review's protocol, responses 
should be provided for each question/entry 
HIGH  LOW  UNCLEAR 
 
Comments: 
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Appendix 3: Newcastle-Ottawa Quality Assessment Scale for Cohort 
Studies 
Selection (Four stars possible) 
1) Representativeness of the exposed cohort 
a) truly representative of the average _______________ (describe) in the community * 
b) somewhat representative of the average ______________ in the community * 
c) selected group of users eg nurses, volunteers 
d) no description of the derivation of the cohort 
2) Selection of the non exposed cohort 
a) drawn from the same community as the exposed cohort * 
b) drawn from a different source 
c) no description of the derivation of the non exposed cohort  
3) Ascertainment of exposure 
a) secure record (eg surgical records) * 
b) structured interview * 
c) written self report 
d) no description 
4) Demonstration that outcome of interest was not present at start of study 
a) yes * 
b) no 
Comparability (Two stars possible) 
1) Comparability of cohorts on the basis of the design or analysis 
a) study controls for _____________ (select the most important factor) * 
b) study controls for any additional factor *  (This criteria could be modified to indicate specific 
control for a second important factor.)  
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Outcome (Three stars possible) 
1) Assessment of outcome  
a) independent blind assessment *  
b) record linkage * 
c) self report  
d) no description 
2) Was follow-up long enough for outcomes to occur 
a) yes (select an adequate follow up period for outcome of interest) * 
b) no 
3) Adequacy of follow up of cohorts 
a) complete follow up - all subjects accounted for *  
b) subjects lost to follow up unlikely to introduce bias - small number lost - > ____ % (select 
an                     adequate %) follow up, or description provided of those lost)  
c) follow up rate < ____% (select an adequate %) and no description of those lost 
d) no statement 
